Publication Information

{'id': 'https://openalex.org/W2969038597', 'doi': 'https://doi.org/10.4103/crst.crst_18_18', 'title': 'Immunotherapy protocols in lung cancer', 'display_name': 'Immunotherapy protocols in lung cancer', 'publication_year': 2018, 'publication_date': '2018-01-01', 'ids': {'openalex': 'https://openalex.org/W2969038597', 'doi': 'https://doi.org/10.4103/crst.crst_18_18', 'mag': '2969038597'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.4103/crst.crst_18_18', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4210179561', 'display_name': 'Cancer Research Statistics and Treatment', 'issn_l': '2590-3225', 'issn': ['2590-3225', '2590-3233'], 'is_oa': True, 'is_in_doaj': True, 'is_core': False, 'host_organization': 'https://openalex.org/P4310320448', 'host_organization_name': 'Medknow', 'host_organization_lineage': ['https://openalex.org/P4310318547', 'https://openalex.org/P4310320448'], 'host_organization_lineage_names': ['Wolters Kluwer', 'Medknow'], 'type': 'journal'}, 'license': 'cc-by-nc-sa', 'license_id': 'https://openalex.org/licenses/cc-by-nc-sa', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'doaj'], 'open_access': {'is_oa': True, 'oa_status': 'diamond', 'oa_url': 'https://doi.org/10.4103/crst.crst_18_18', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5054959453', 'display_name': 'Sharada Mailankody', 'orcid': 'https://orcid.org/0000-0003-2003-426X'}, 'institutions': [{'id': 'https://openalex.org/I2800098698', 'display_name': 'Tata Memorial Hospital', 'ror': 'https://ror.org/010842375', 'country_code': 'IN', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800098698']}], 'countries': ['IN'], 'is_corresponding': True, 'raw_author_name': 'Sharada Mailankody', 'raw_affiliation_strings': ['Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India', 'Dr. Sharada Mailankody, Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra, India. E-mail: [email\xa0protected]'], 'affiliations': [{'raw_affiliation_string': 'Dr. Sharada Mailankody, Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra, India. E-mail: [email\xa0protected]', 'institution_ids': ['https://openalex.org/I2800098698']}, {'raw_affiliation_string': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India', 'institution_ids': ['https://openalex.org/I2800098698']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5110718606', 'display_name': 'Nandini Menon', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2800098698', 'display_name': 'Tata Memorial Hospital', 'ror': 'https://ror.org/010842375', 'country_code': 'IN', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800098698']}], 'countries': ['IN'], 'is_corresponding': False, 'raw_author_name': 'Nandini Menon', 'raw_affiliation_strings': ['Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India'], 'affiliations': [{'raw_affiliation_string': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India', 'institution_ids': ['https://openalex.org/I2800098698']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5054959453'], 'corresponding_institution_ids': ['https://openalex.org/I2800098698'], 'apc_list': {'value': 0, 'currency': 'USD', 'value_usd': 0, 'provenance': 'doaj'}, 'apc_paid': None, 'fwci': 0.527, 'has_fulltext': False, 'cited_by_count': 9, 'citation_normalized_percentile': {'value': 0.845939, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 84, 'max': 85}, 'biblio': {'volume': '1', 'issue': '2', 'first_page': '139', 'last_page': '139'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9987, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12334', 'display_name': 'Lung Cancer Research Studies', 'score': 0.997, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/atezolizumab', 'display_name': 'Atezolizumab', 'score': 0.9680128}, {'id': 'https://openalex.org/keywords/durvalumab', 'display_name': 'Durvalumab', 'score': 0.95759094}, {'id': 'https://openalex.org/keywords/avelumab', 'display_name': 'Avelumab', 'score': 0.45065212}], 'concepts': [{'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.971047}, {'id': 'https://openalex.org/C2775949291', 'wikidata': 'https://www.wikidata.org/wiki/Q20707748', 'display_name': 'Atezolizumab', 'level': 5, 'score': 0.9680128}, {'id': 'https://openalex.org/C2777742743', 'wikidata': 'https://www.wikidata.org/wiki/Q19904005', 'display_name': 'Durvalumab', 'level': 5, 'score': 0.95759094}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.93506885}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.86737347}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.7161112}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.6860435}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.59208786}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.5560086}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5227942}, {'id': 'https://openalex.org/C2781053074', 'wikidata': 'https://www.wikidata.org/wiki/Q21100639', 'display_name': 'PD-L1', 'level': 4, 'score': 0.5165745}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.49525228}, {'id': 'https://openalex.org/C2777381376', 'wikidata': 'https://www.wikidata.org/wiki/Q21083261', 'display_name': 'Avelumab', 'level': 5, 'score': 0.45065212}, {'id': 'https://openalex.org/C177713679', 'wikidata': 'https://www.wikidata.org/wiki/Q679690', 'display_name': 'Intensive care medicine', 'level': 1, 'score': 0.4064945}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.38700575}], 'mesh': [], 'locations_count': 3, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.4103/crst.crst_18_18', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4210179561', 'display_name': 'Cancer Research Statistics and Treatment', 'issn_l': '2590-3225', 'issn': ['2590-3225', '2590-3233'], 'is_oa': True, 'is_in_doaj': True, 'is_core': False, 'host_organization': 'https://openalex.org/P4310320448', 'host_organization_name': 'Medknow', 'host_organization_lineage': ['https://openalex.org/P4310318547', 'https://openalex.org/P4310320448'], 'host_organization_lineage_names': ['Wolters Kluwer', 'Medknow'], 'type': 'journal'}, 'license': 'cc-by-nc-sa', 'license_id': 'https://openalex.org/licenses/cc-by-nc-sa', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://doaj.org/article/30d4c9ddb3544b259049af0da3485905', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306401280', 'display_name': 'DOAJ (DOAJ: Directory of Open Access Journals)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://journals.lww.com/crst/abstract/2018/01020/immunotherapy_protocols_in_lung_cancer.11.aspx', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.4103/crst.crst_18_18', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4210179561', 'display_name': 'Cancer Research Statistics and Treatment', 'issn_l': '2590-3225', 'issn': ['2590-3225', '2590-3233'], 'is_oa': True, 'is_in_doaj': True, 'is_core': False, 'host_organization': 'https://openalex.org/P4310320448', 'host_organization_name': 'Medknow', 'host_organization_lineage': ['https://openalex.org/P4310318547', 'https://openalex.org/P4310320448'], 'host_organization_lineage_names': ['Wolters Kluwer', 'Medknow'], 'type': 'journal'}, 'license': 'cc-by-nc-sa', 'license_id': 'https://openalex.org/licenses/cc-by-nc-sa', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being', 'score': 0.87}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4353088123', 'https://openalex.org/W4293000990', 'https://openalex.org/W3040716217', 'https://openalex.org/W3031689938', 'https://openalex.org/W2969038597', 'https://openalex.org/W2894742494', 'https://openalex.org/W2884534038', 'https://openalex.org/W2749169318', 'https://openalex.org/W2734670400', 'https://openalex.org/W2504822853'], 'abstract_inverted_index': {'Immunotherapy': [0], 'has': [1], 'emerged': [2], 'as': [3], 'a': [4], 'valuable': [5], 'treatment': [6], 'option': [7], 'in': [8, 33, 38], 'many': [9], 'advanced': [10], 'malignancies': [11], '(especially': [12], 'lung': [13], 'cancer).': [14], 'The': [15, 42, 52], 'PD-1': [16], 'inhibitors': [17, 24], '(nivolumab': [18], 'and': [19, 21, 26, 64], 'pembrolizumab)': [20], 'the': [22, 45, 67], 'PD-L1': [23], '(durvalumab': [25], 'atezolizumab)': [27], 'have': [28], 'been': [29], 'approved': [30], 'for': [31, 44, 55, 66], 'use': [32], 'various': [34, 53], 'cancers,': [35], 'alone': [36], 'or': [37], 'combination': [39], 'with': [40], 'chemotherapy.': [41], 'protocols': [43], 'PD-1/PD-L': [46], '1': [47], 'blockers': [48], 'are': [49, 73], 'listed': [50], 'below.': [51, 75], 'indications': [54], 'these': [56], 'PD-1/PD-L1': [57], 'blockers,': [58], 'baseline': [59], 'evaluation,': [60], 'monitoring': [61], 'during': [62], 'therapy,': [63], 'guidelines': [65], 'management': [68], 'of': [69], 'immune-related': [70], 'adverse': [71], 'events': [72], 'described': [74]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2969038597', 'counts_by_year': [{'year': 2024, 'cited_by_count': 2}, {'year': 2023, 'cited_by_count': 1}, {'year': 2022, 'cited_by_count': 1}, {'year': 2021, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 1}, {'year': 2019, 'cited_by_count': 3}], 'updated_date': '2024-12-13T10:58:44.159987', 'created_date': '2019-08-22'}